The EUGOGO consensus statement on the management of Graves' orbitopathy: Equally applicable to North American clinicians and patients

Thyroid

Volumn 18, Issue 3, 2008, Pages 281-282

  Bahn, Rebecca ^a,b  

^a American Thyroid Association

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; METHYLPREDNISOLONE; STEROID;

CLINICAL PRACTICE; CONFERENCE PAPER; CONSENSUS; DOSE RESPONSE; ENDOCRINE OPHTHALMOPATHY; EYE DISEASE; HUMAN; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; NORTH AMERICA; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

CONSENSUS; ENDOCRINOLOGY; EVIDENCE-BASED MEDICINE; GRAVES OPHTHALMOPATHY; HUMANS; NORTH AMERICA; PRACTICE GUIDELINES AS TOPIC;

EID: 40949114984     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0034     Document Type: Conference Paper

References (3)

1. Bartalena L, Baldeschi L, Dickenson A, et al. 2007 Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on the management of Graves' orbitopathy. Thyroid 18:333-346.
2. Weissel M, Hauff W 2000 Acute and fatal liver failure after high-dose glucocorticoid pulse therapy in a patients with severe eye disease. Thyroid 10:521.
3. Marino M, Morabito Brunette MR, Bartalena L, Pinchera A, Marcocci C 2004 Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 14:403-406.